ConductScience.org, home

Paper26817954

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.

Araki M and 12 others. Blood, 2016. Cited by 249 papers, by iCite.

Cite this record

ConductScience Library. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Papers, record 26817954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26817954

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
PubMed
Journal
Blood
PubMed
Year
2016
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
249
iCite
Relative citation ratio, by iCite
7.54
iCite
Revised in PubMed
2021-05-03
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Araki MMarito
2Yang YYinjie
3Masubuchi NNami
4Hironaka YYumi
5Takei HHiraku
6Morishita SSoji
7Mizukami YYoshihisa
8Kan SShin
9Shirane SShuichi
10Edahiro YYoko
11Sunami YYoshitaka
12Ohsaka AAkimichi
13Komatsu NNorio

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CalreticulinMajor topic
Hematologic NeoplasmsMajor topic
Myeloproliferative DisordersMajor topic
Neoplasm ProteinsMajor topic
Receptors, ThrombopoietinMajor topic
Cell Line, Tumor
HEK293 Cells
Humans
Induced Pluripotent Stem Cells
Janus Kinase 2
Phosphorylation
Protein Structure, Tertiary
Thrombopoiesis
Thrombopoietin

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in26965919Mutant calreticulin: when a chaperone becomes intrusive.https://conductscience.org/library/papers/26965919

Source PubMed

Download CSV of comments and corrections

Cited by174

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 249 citations.

PMIDTitleJournalYearIn PapersSource
42956057Molecular and functional analysis of calcium binding by a cancer-linked calreticulin mutant.Elife2026https://conductscience.org/library/papers/42956057PubMed
42919838How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?Bone Marrow Transplant2026https://conductscience.org/library/papers/42919838PubMed
42860554Haematopoietic Cells Deficient for Calreticulin or Expressing Its Oncogenic Variants Maintain Functional Antigen Presentation.J Cell Mol Med2026https://conductscience.org/library/papers/42860554PubMed
42792882The Roles of Genetic and Epigenetic Abnormalities in Essential Thrombocythemia.Genes (Basel)2026https://conductscience.org/library/papers/42792882PubMed
42786200Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.Leukemia2026https://conductscience.org/library/papers/42786200PubMed
42745000Type 1 interferon perturbates clonal competition by reshaping human blood development.Nat Genet2026https://conductscience.org/library/papers/42745000PubMed
42689321Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.Arterioscler Thromb Vasc Biol2026https://conductscience.org/library/papers/42689321PubMed
42650032Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities.Cancers (Basel)2026https://conductscience.org/library/papers/42650032PubMed
42613432Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.Leukemia2026https://conductscience.org/library/papers/42613432PubMed
42545540Calreticulin as a stress-responsive integrator of ER proteostasis, calcium homeostasis, and immune clearance.Mol Biol Rep2026https://conductscience.org/library/papers/42545540PubMed
42346284Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms.Diseases2026https://conductscience.org/library/papers/42346284PubMed
42230475Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms.Int J Hematol2026https://conductscience.org/library/papers/42230475PubMed
42131291CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.Hemasphere2026https://conductscience.org/library/papers/42131291PubMed
41959476Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease.bioRxiv2026https://conductscience.org/library/papers/41959476PubMed
41798678Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms.Blood Neoplasia2026https://conductscience.org/library/papers/41798678PubMed
41532194A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.Am J Hematol2026https://conductscience.org/library/papers/41532194PubMed
41228192Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.Cancers (Basel)2025https://conductscience.org/library/papers/41228192PubMed
41195513Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.Haematologica2026https://conductscience.org/library/papers/41195513PubMed
41087184[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations].Zhonghua Xue Ye Xue Za Zhi2025https://conductscience.org/library/papers/41087184PubMed
40857671Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Blood2026https://conductscience.org/library/papers/40857671PubMed

See all 174 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CALR811PubTator's text mininghttps://conductscience.org/library/genes/811NCBI Gene
JAK23717PubTator's text mininghttps://conductscience.org/library/genes/3717NCBI Gene
MPL4352PubTator's text mininghttps://conductscience.org/library/genes/4352NCBI Gene
THPO7066PubTator's text mininghttps://conductscience.org/library/genes/7066NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26817954

GET https://conductscience.org/api/papers/v1/26817954/cited_by?page=2